A phase II study of bortezomib in patients with MALT lymphoma

Haematologica

Volumn 94, Issue 5, 2009, Pages 738-742

  Troch, Marlene ^a   Jonak, Constanze ^a   Müllauer, Leonhard ^a   Püspök, Andreas ^a   Formanek, Michael ^b   Hauff, Wolfgang ^a   Zielinski, Christoph C ^a   Chott, Andreas ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Division of Internal Medicine III ^*

Author keywords

Bortezomib; Chemotherapy; MALT lymphoma

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; FEVER; FOLLOW UP; HUMAN; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; RASH; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NAUSEA; NERVOUS SYSTEM DISEASES; PYRAZINES; TREATMENT OUTCOME;

EID: 66049158676     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.001537     Document Type: Article

References (22)

1. Pileri SA, Milani M, Fraternali-Orcioni G, Sabattini E. From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? Ann Oncol 1998;9:607-612
2. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low grade Bcell gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet 1993;342:575-577
3. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long-term outcome of patients with gastric marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004;53:34-37 (Pubitemid 38083007)
4. Fischbach W, Goebeler ME, Ruskone- Fourmestraux A, Wündisch T, Neubauer A, Raderer M, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. EGILS (European Gastro- Intestinal Lymphoma Study) Group. Gut 2007;56:1685-1687
5. Jäeger G, Neumeister P, Brezinschek R, Höfler G, Quehenberger F, Linkesch W, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-3877
6. Wöhrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Püspök A, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 2003;14:1758-1761
7. Jäger G, Neumeister P, Quehenberger F, Wöhrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17:1722-1723 (Pubitemid 44680898)
8. Ben Simon Guy J, Cheung N, McKelvie P, Fox R, McNab AA. Oral chlorambucil for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. Ophthalmology 2006;113:1209-1213 (Pubitemid 43947228)
9. Avilés A, Nambo MJ, Neri N, Talavera A, Cleto S. Mucosa associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005;22:57-62. (Pubitemid 40647230)
10. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-431. Blood 2003;101:1530-1534
11. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374-14379
12. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell lymphoma. J Clin Oncol 2005; 23:667-675
13. Isaacson P, Müller-Hermelink HK, Piris MA. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Jaffe ES, Harris NL, editors. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. p 157-160
14. Wöhrer S, Troch M, Streubel B, Hoffmann M, Müllauer L, Chott A, et al. Pathology and clinical course of MALT-lymphoma with plasmacytic differentiation. Ann Oncol 2007;18: 2020-2024
15. Wöhrer S, Streubel B, Bartsch R, Chott A, Raderer M. Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. Clin Cancer Res 2004;10:7179-7181 (Pubitemid 39487703)
16. Raderer M, Wöhrer S, Streubel B, Troch M, Turetschek K, Jäger U, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single center experience. J Clin Oncol 2006;24:3136-3141 (Pubitemid 46646224)
17. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa associated lymphoid tissue: factors relevant to prognosis. Gastroenterology 1992; 102:1628-1638
18. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244.
19. Copie-Bergman C, Gaulard P, Lavergne-Slove A, Brousse N, Fléjou JF, Dordonne K, et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT-lymphoma. Gut 2003;52: 1656.
20. Smimon R. Design and Conduct of clinical trials. Cancer: Principles & Practice of Oncology, Fourth Edition. 1993. p. 418-440
21. Raderer M, Wohrer S, Streubel B, Drach J, Jager U, Turetschek K, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006;70:411-417
22. Zinzani P, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, et al. Fludarabine containing chemotherapy as frontline treatment of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004;100: 2190-2194